Samuel Dakil, MD
Urology · Norman, OKNPI 1710948831
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.0% of the total across 208 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Medtronic at 32.3% of the total.
Across 208 payments — averaging $27.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Astellas Pharma US Inc$809
- Axonics, Inc.$775
- Coloplast$476
- Boston Scientific$394
- Neotract Inc.$245
- plus $1K from 23 others
What the payments were for
- Speaking & faculty fees$2584%
- Travel & lodging$70%
- Food & beverage$5,21191%
- Education$2524%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 62 | $1,852 |
| Astellas Pharma US Inc | 47 | $809 |
| Axonics, Inc. | 12 | $775 |
| Coloplast | 15 | $476 |
| Boston Scientific | 19 | $394 |
| Neotract Inc. | 4 | $245 |
| Pfizer | 11 | $230 |
| Palette Life Sciences, Inc. | 2 | $173 |
| Laborie Medical Technologies Corp. | 2 | $134 |
| Teleflex LLC | 3 | $93 |
| Myriad Genetic Laboratories, Inc. | 4 | $72 |
| Johnson & Johnson | 2 | $54 |
| Dendreon Pharmaceuticals LLC | 3 | $49 |
| Sumitomo Pharma America, Inc. | 3 | $47 |
| Antares Pharma, Inc. | 3 | $42 |
| AbbVie(2 entities) | 2 | $37 |
| Accord Healthcare, Inc. | 2 | $33 |
| Myovant Sciences Inc. | 1 | $24 |
| Merck | 1 | $24 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Healthtronics Stone Solutions, LLC | 1 | $21 |
| Urogen Pharma, Inc. | 1 | $20 |
| Bayer | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Olympus America Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Clarus Therapeutics Inc. | 1 | $14 |
| Tolmar Pharmaceuticals, Inc. | 1 | $11 |
| Mission Pharmacal Company | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$644
- Axonics$471
- UroLift$116
- Optilume BPH Drug Coated Balloon Catheter$114
- Bulkamid$105
How this compares
$5,727 in reported general payments places this provider in the 60th percentile of 145 urology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 44 | $608,384 |
| MyrbetriqMirabegron | 529 | $509,394 |
| GemtesaVibegron | 37 | $34,648 |
| Abiraterone Acetate | 20 | $30,798 |
| Solifenacin Succinate | 519 | $25,027 |
| ElmironPentosan Polysulfate Sodium | 15 | $18,876 |
| Trospium Chloride ErTrospium Chloride | 52 | $14,867 |
| Tamsulosin Hcl | 711 | $11,231 |
| Trospium Chloride | 130 | $11,021 |
| NitrofurantoinNitrofurantoin Macrocrystal | 213 | $7,738 |
| Tolterodine Tartrate ErTolterodine Tartrate | 78 | $7,516 |
| Trimethoprim | 105 | $6,209 |
| Potassium Citrate ErPotassium Citrate | 30 | $4,216 |
| Estradiol | 39 | $3,209 |
| Finasteride | 206 | $3,179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $809 | $1,117,778573 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $47 | $34,64837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 145 urology providers in Oklahoma.
Other urology in Norman
- Bradley WilsonNorman$10K
- Mohammad RamadanOklahoma City$207K
- Michael CooksonOklahoma City$132K
- Melanie KetchandjiTulsa$111K
- Kelly StrattonOklahoma City$62K
- Ashley BowenOklahoma City$32K
- Marc MilstenTulsa$29K
- Scott LitwillerTulsa$27K
- Sardar Mohammad Khan GalzieOklahoma City$25K
- Charles PritchardTulsa$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.